In healthcare, it is tempting to treat distribution as the step that comes after the real work — develop or source the product first, then find someone to carry it. In the Indian market, that sequence quietly destroys value. How a product will reach its market deserves as much attention as what the product is, and the best results come from deciding both together.
Why the sequence matters
India's pharmaceutical distribution runs through a layered network — carrying-and-forwarding agents, stockists, sub-stockists, retail chemists — with institutional and hospital supply following different rules again, and consumer channels (modern trade, e-commerce, beauty retail) different rules still. Each layer has its own economics: margins, credit periods, minimum volumes, and expectations about who generates demand.
A product conceived without a channel in mind arrives at this network as a negotiation from weakness. The company needs the channel more than the channel needs the product, and the terms reflect that. A product conceived for a channel arrives as a fit: the pack size suits the counter, the price point suits the margin structure, the range gives the stockist a reason to care.
What deciding together looks like
Range before SKU. A distributor's real question is rarely about one product; it is about whether your range justifies a relationship. Introducing products in coherent groups — a family of variants, a therapy-area set — changes the answer. This is where portfolio strategy and distribution strategy turn out to be the same subject.
Pack and price as channel decisions. The same formulation can succeed or fail on pack size and price point alone, because these determine which counter it can sit on and what margin each layer earns. These are commercial decisions with a channel logic, not afterthoughts for the artwork stage.
Demand generation matched to the channel. Prescription products need field presence with prescribers; consumer products need visibility where consumers decide; institutional supply needs tendering discipline and documentation. A channel choice is also a commitment to a particular way of creating demand — and to its costs.
Territory honesty. A network that covers a state deeply beats a map that claims a country thinly. Distributors judge partners by whether promised support actually arrives in their territory. Growing territory by territory — with the supply, stock and attention each one needs — builds the reputation that makes the next territory easier.
The partnership consequence
Thinking this way changes what a company looks for in distribution partners, and what it offers them. The relationship stops being transactional — "carry our product" — and becomes structural: a range worth investing in, terms that respect the channel's economics, and demand generation the channel can see. Distributors extend their best attention to companies that make them money predictably, and that is a design outcome, not a persuasion outcome.
It also changes internal decisions. A product opportunity that looks attractive in isolation may fail the channel test: no fit with the network the company actually has, or economics that leave no room for the layers that must carry it. Declining such opportunities is not lost revenue; it is the discipline that keeps the network strong.
At Aromentis, market access is not a department that receives finished products — it is a consideration present in the first conversation about any product. The portfolio and the pathway are designed together, because in this market they succeed or fail together.